Peanuts and Glycemic Control
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 1/19/2019 |
| Start Date: | October 1, 2018 |
| End Date: | December 1, 2019 |
| Contact: | Kristina S Petersen, PhD |
| Email: | kup63@psu.edu |
| Phone: | 8148638622 |
The Role of the Microbiome in Blood Glucose Regulation in Response to Peanut Consumption
A two-period randomized crossover study will be conducted to determine the effect of peanuts
on glycemic control, and elucidate the role of the microbiome in glucose regulation, in
individuals with impaired fasting glucose.
on glycemic control, and elucidate the role of the microbiome in glucose regulation, in
individuals with impaired fasting glucose.
A two-period randomized crossover trial will be conducted. Participants will be randomized to
receive each treatment for 6 weeks followed by a minimum 4-week wash-out period. During the
peanut treatment, participants will consume one ounce per day (28 g) of peanuts as an evening
snack. The control treatments will be an isocaloric higher carbohydrate snack consumed after
the evening meal. Markers of glycemic control, cardiovascular risk factors and gut health
will be assessed at the beginning and the end of each treatment period.
receive each treatment for 6 weeks followed by a minimum 4-week wash-out period. During the
peanut treatment, participants will consume one ounce per day (28 g) of peanuts as an evening
snack. The control treatments will be an isocaloric higher carbohydrate snack consumed after
the evening meal. Markers of glycemic control, cardiovascular risk factors and gut health
will be assessed at the beginning and the end of each treatment period.
Inclusion Criteria:
- Non-smoking
- Impaired fasting glucose at screening (≥ 100 mg/dL).
- BMI ≥20 and ≤40 kg/m2.
Exclusion Criteria:
- Diagnosed diabetes or fasting glucose >126 mg/dl
- Systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg)
- Prescribed anti-hypertensive, lipid lowering or glucose lowering drugs
- Established cardiovascular disease, stroke, diabetes, liver, kidney or autoimmune
disease or inflammatory conditions
- Use of supplements (psyllium, fish oil, soy lecithin, phytoestrogens) and botanicals
and not willing to cease for the duration of the study
- Pregnancy or lactation
- Weight loss of >=10% of body weight within the 6 months prior to enrolling in the
study
- Smoking or use of any tobacco products
- Allergy to test foods
- Consumption of >14 alcoholic drinks/week
We found this trial at
1
site
Click here to add this to my saved trials
